Article Text

Download PDFPDF

Correspondence response
Response to: ‘Does MOVES move the needle?’ by Dr Meyer
  1. Marc C Hochberg,
  2. on behalf of the MOVES Investigation Group
  1. University of Maryland School of Medicine, Baltimore, Maryland, USA
  1. Correspondence to Marc C Hochberg, University of Maryland School of Medicine, 10 S. Pine St., MSTF 8–34, Baltimore, MD 21201, USA; mhochber{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Meyer1 for his comments on the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT)2 and the Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES).3

In GAIT, carried out during 2000–2004, 1583 patients with symptomatic knee osteoarthritis (OA) were randomised to glucosamine, chondroitin sulfate, glucosamine plus chondroitin sulfate, celecoxib or placebo. As Dr Meyer pointed out, there was a strong placebo response; after 24 weeks, 60.1% of the placebo group had a 20% decrease in Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain score (primary outcome). However, Dr Meyer said that ‘GAIT failed to show a difference for any treatment in the change from baseline’; the response rates in the four treatment groups were 64.0% for …

View Full Text

Linked Articles

  • Electronic pages
    Robert Meyer